Welcome Guest
Home » Reports » T-Cell Immunotherapy Market (2nd Edition), 2017-2030

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

Published: Jan 13, 2017
Pages: 654
Product Code: RA10074
License Type :  (Learn More)

The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments of the pharmaceutical industry. Harnessing immune system components for developing therapeutic solutions has demonstrated significant clinical benefit for various diseases areas, specifically against a number of oncological indications. Immunotherapeutics have gradually gained a strong foothold in the pharmaceutical industry. Post the early success of immune checkpoint inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.

 

Adoptive immunotherapy is an emerging concept that involves the passive transfer of immune cells, which may or may not be modified / genetically altered to express a desired set of traits and / or features.Characterized by key features such as target specificity, adaptability and the capability to retain immunologic memory, T-cells have been effectively used as therapeutic tools to mediate an artificial immune response. More specifically, T-cell immunotherapies are classified into three major segments, namely chimeric antigen receptor (CAR) T-cell, T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) based therapies. Academicians across the globe have significantly contributed to this field by convening the initial research on potential product candidates; this has served as the intellectual framework for establishment of several start-ups and evolution of the product portfolios of established players in the industry.

 

The overall market is expected to witness a significant growth in opportunities for a variety of stakeholders in the coming decade. It is important to highlight that various technology providers, aiming to develop and / or support the development of T-cell immunotherapy products with improved efficacy and safety, have designed and introduced advanced platforms for engineering of T-cells. Innovation in this domain, backed by lucrative rounds of venture capital (VC) funding, has led to the discovery of several novel molecular targets and strengthened the research pipelines of companies focused in this space. The capability to target diverse therapeutic areas is amongst the most prominent growth drivers of this market.

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The “T-Cell Immunotherapy Market, 2017-2030 (2nd edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders. The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies.

 

The role of academic players / research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis / University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma / National Cancer Institute), and LN-144 (Lion Biotechnologies / National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies.

 

Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population.

 

One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following areas:

  • The current state of the market with respect to key players, developmental stages of pipeline products (both clinical / preclinical) and target therapeutic indications. In addition, we have also provided an overview of the competitive landscape, key challenges and anticipated future trends within the three major types of T-cell based therapies.
  • Detailed profiles of candidate therapies that are in the mid to late stages of development (phase I/II or above).
  • The partnerships that have been established in the recent past, covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product development / commercialization agreements, clinical trial collaborations and joint venture agreements.
  • Details of innovative technological platforms, such as safety switches, which have contributed significantly in overcoming existing gaps in the therapeutic regimen.
  • An analysis of the various investments, grants and other types of funding provided to companies focused in this area.
  • An overview of the various therapeutic areas being addressed by therapy developers, including an assessment of the opportunity offered by both oncological and non-oncological disease indications.
  • A discussion on the emerging trends on social media and on the popularity of T-cell immunotherapy products on Twitter over the last few years.
  • Details on novel T-cell immunotherapies that are being investigated, along with their respective mechanisms of action.
  • A detailed case study on the manufacturing of cell therapy products, highlighting key challenges and a list of contract service providers and in-house manufacturers that are involved in this space.
  • A discussion on the development and sales potential based on target consumer segments, likely adoption rates and expected pricing based upon different models / approaches.

 

With most products still in the early stages of clinical development, we have provided informed estimates of the potential future sales of different CAR-T, TCR and TIL therapies. The research, analysis and insights presented in this report are backed by a deep understanding of the key drivers behind the predicted growth. We have provided three market forecast scenarios to add robustness to our model. More specifically, the conservative, base and optimistic forecast scenarios represent three different tracks of the industry’s evolution, taking into account the ambiguities associated with the development and approval of pharmaceutical products. All actual figures have been sourced from publicly available information. All figures mentioned in this report are in USD, unless otherwise specified.

 

Example Highlights

  1. During the course of our research, we identified around 280 T-cell therapies being evaluated across various phases of development. Among these, CAR-T cell products are the most common (67%), followed by TCR (23%) and TIL (10%) based therapies.
  2. Overall, 29% of the pipeline therapies are being evaluated in phase II / phase III clinical trials; on the other hand, 38% of the therapies are in the preclinical / discovery stage of development. Examples of promising late-stage therapies include CTL-019 (Novartis), JCAR015 (Juno Therapeutics), KTE-C19 and HPV-16 E6 TCR (Kite Pharma), NY-ESO-1 TCR (Adaptimmune / GSK), LN-144 (Lion Biotechnologies), ALT801 (Altor BioScience) and IMCgp100 (Immunocore).
  3. Academic institutions are the leading innovators in this domain. Many universities and research institutes have made significant contributions by investing time and building expertise in the design and development of novel CAR-Ts, TCRs and TILs. We observed that non-industry players are involved in the development of around 50% of all the therapies currently in the pipeline. The most active non-industry players (based upon the number of therapies under development) include the National Cancer Institute, MD Anderson Cancer Center, Baylor College of Medicine, University of Pennsylvania, Chinese PLA General Hospital, Southwest Hospital, Fred Hutchinson Cancer Research Center, Fuda Cancer Hospital, Memorial Sloan Kettering Cancer Center, Uppsala University and City of Hope Medical Center.
  4. The market is highly fragmented and characterized by the presence of several start-ups, small pharma and big pharma firms.The key players involved in development of T-cell therapies (based upon the number of candidate therapies in their respective product pipelines) include Juno Therapeutics, Shanghai Genechem, Kite Pharma, Cellular Biomedicine Group, Lion Biotechnologies, Takara Bio, Celgene, Adaptimmune and ZIOPHARM Oncology. AURORA BioPharma, Beijing Doing Biomedical, Bellicum Pharmaceuticals, CARsgen Therapeutics, iCarTABBioMed, Intrexon, Mustang Bio, Novartis, Sinobioway Cell Therapy, Unum Therapeutics and Shionogi are other players that have more than one clinical stage therapies.
  5. In addition to some of the companies outlined above, there are several other start-ups that are focused in this domain; these include (in alphabetical order) Altor BioScience, Autolus, Adicet Bio, Catapult Therapy TCR, Chimeric Therapeutics, Formula Pharmaceuticals, Gadeta, Immatics US, JW Biotechnology, Lion TCR, Leucid Bio, Mustang Therapeutics, Poseida Therapeutics, TILT Biotherapeutics, TNK Therapeutics, Tmunity Therapeutics and Vor Biopharma.
  6. Stakeholders have forged synergistic partnerships in order to exploit the commercial potential of their respective assets. Overall, we identified more than 135 partnerships that have been inked in the T-cell immunotherapy field over the period 2005-2016. Most common forms of partnerships were related to research (20%), followed by technology licensing (15%), product discovery, development and commercialization (12%), manufacturing (11%), clinical trials (7%) and acquisitions (7%).
  7. Amidst several challenges, including the complexities associated with manufacturing cell-based products, and competition from existing drug / therapy classes (such as monoclonal antibodies, bi-specific antibodies and immune checkpoint inhibitors), therapy developers are engaged in extensive research in order to effectively deal with these issues. Several contract manufacturing organizations with advanced capabilities have emerged to provide manufacturing services for the personalized T-cell based therapies. Examples of the CMOs providing manufacturing services for T-cell therapies include apcethBiopharma, Atlantic Bio GMP, Cell and Gene Therapy Catapult, Cell Therapies, CELLforCURE, Cellular Therapeutics, MolMed and PCT (a Caladrius company).
  8. A number of technological advancements have taken place in order to support the development of these therapies; engineered CAR-Ts with switch technologies are amongst the latest additions to next-generation T-cell immunotherapies. Funding from VC firms and strategic investors has been a key enabler to the market’s growth. Notably, close to USD 5 billion has been invested in this domain over the past few years. Several big ticket investments have recently taken place. For instance, Immunocore raised USD 320 million in July 2015, Kite Pharma raised USD 288 million in December 2015 and Cellectis raised USD 228 million in March 2015.
  9. A variety of novel types of immunotherapies, other than CAR-T, TCR and TIL, are expected to emerge in the mid-long term. Companies such as TxCell, Caladrius Biosciences, TRACT Therapeutics, Green Cross Cell and Tmunity Therapeutics, are developing T-regulatory cell based therapies. Other players, namely Opexa Therapeutics, TVAX and Immunovative Therapies, are developing T-cell based vaccines for treating autoimmune disorders and various forms of cancer. Further, Atara Biotherapeutics, Cell Medica and Tessa Therapeutics are working on the development of virus-driven T-cell therapies. A number of companies have developed unique technology platforms based on T-cells. Examples include Targazyme (Fucosylated T-cells), Triumvira (TAC-T cells), Chengdu MedGenCell (PD-1 Knockout Engineered T-cells) and GammaCell Bio-Technologies (γδ T-cells).
  10. Overall, we believe the T-cell therapy market is likely to be worth USD 25 billion by 2030, expanding at an annualized growth rate of over 101% during this time period. Specifically, by 2030, the markets for CAR-T and TCR therapies market are likely to be worth over USD 11 billion each.Product candidates, such as KTE-C19, CTL019, NY-ESO-1 TCR, ALT 801 and JCAR017, are expected to emerge as potential blockbusters in the long term.

 

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The various secondary sources of information that we use include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.

 

Chapter 3 provides a general introduction to T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of oncological indications, the advent of cancer immunotherapy and the factors supporting the growing popularity of T-cell based therapies.

 

Chapter 4 provides a comprehensive overview of the current landscape of the T-cell immunotherapy market. It features information on various types of therapies that are currently in different stages of development (clinical and preclinical / discovery). It includes a detailed analysis of the T-cell immunotherapy pipeline, specifically, providing information on the most commonly targeted disease indications, current phases of development of individual therapies, specific molecular targets, type of developer(s) and the key companies involved in the development of different types of T-cell therapies, namely CAR-T, TCR and TIL.

 

Chapter 5 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

 

Chapter 6 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

 

Chapter 7 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

 

Chapter 8 features an elaborate discussion on the future opportunity presented by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are in the advanced stages of development (phase I/II, phase II and phase II/III), taking into consideration the target patient population, existing competition, likely adoption rates and the likely price of T-cell therapies.

 

Chapter 9 provides an analysis of the various T-cell therapies that are being developed for the treatment of commonly targeted indications, including hematological cancers and solid tumors. It is worth mentioning that the aforementioned types of oncological indications have been the prime focus of companies developing T-cell immunotherapies. The section also highlights key epidemiological facts and the currently available treatment solutions for each indication.

 

Chapter 10 focuses on emerging technological platforms that mediate/assist the growth of the T-cell market. It includes detailed discussions on various novel and innovative technologies, along with brief information about key technology providers.

 

Chapter 11 provides an overview of the emerging trends related to T-cell immunotherapy on social media. It includes data representing the popularity of T-cell products on Twitter over the last five years.

 

Chapter 12 presents a detailed analysis on the partnerships and agreements established between various players concerning T-cell immunotherapies in the past few years. The section also highlights the financial details of the agreements (wherever available). The partnership activity in this domain has been analyzed on the basis of the year of establishment of the company, the type of partnership model employed, the companies involved, therapy type and prominent product candidates involved.

 

Chapter 13 provides details on the various investments and grants awarded to players focused on the development of T-cell immunotherapies. The analysis highlights the growing interest of the VC community and other strategic investors in this domain.

 

Chapter 14 offers details of other novel T-cell based technologies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. We have provided a brief overview of these upcoming therapies, along with details of their mechanisms of action and the process followed for dose administration.

 

Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities.For these players, we have included details, such as the scale of operation, compliance to cGMP standards, location of various manufacturing facilities and the products being manufactured.

 

Chapter 16 highlights our view point on the various factors that must be considered while pricing the cell based therapies. It features discussions on different models / approaches that a pharmaceutical company can follow to decide the price at which their T-cell based immunotherapy product is likely to be marketed.

 

Chapter 17 includes detailed company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes information such as financial performance, geographical presence, T-cell immunotherapy pipeline, collaborations and recent developments. Additionally, we have also provided details of the strategic / venture capital investments made in these companies.

 

Chapter 18 is a collection of transcripts of interviews conducted during the course of this study. In this chapter, we have presented the details of our conversations with Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Lion Biotechnologies), AinoKalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma) and Miguel Forte (Chief Operating Officer, TxCell).

 

Chapter 19 summarizes the entire report. Here, we have provided a list of key takeaways and our independent opinion on the current state and future opportunity in this field.

 

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures in the report.

 

Chapter 21 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

 

 
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining a Strong Foothold
3.4. Immuno-Oncology: Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Cell Based Therapies
 
3.6. T-Cell Immunotherapy: Historical Evolution
3.7. T-Cell Immunotherapy: Key Considerations
3.8. Strategies Employed for Redirection of T-Cells
3.9. T-Cell Transduction / Transfection Methods
3.9.1. Retroviral Vectors
3.9.2. Lentiviral Vectors
3.9.3. Non-viral Transfection Methods
3.9.3.1. Sleeping Beauty Transposon
3.10. T-Cell Immunotherapy: Targeted Therapeutic Areas
3.11. T-Cell Immunotherapy: Key Challenges
 
4. Market Landscape
4.1. Chapter Overview
4.2. T-Cell Immunotherapy: An Evolving Landscape
4.3. T-Cell Immunotherapy: A Promising Pipeline
4.3.1. T-Cell Immunotherapy: CAR-T Cells
4.3.1.1. Clinical Pipeline
4.3.1.2. Preclinical / Discovery Pipeline
4.3.2. T-Cell Immunotherapy: TCR Cells
4.3.2.1. Clinical Pipeline
4.3.2.2. Preclinical / Discovery Pipeline
4.3.3. T-Cell Immunotherapy: TIL Cells
4.3.3.1. Clinical Pipeline
4.3.3.2. Preclinical / Discovery Pipeline
4.4. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Product
4.5. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Developer
4.6. T-Cell Immunotherapy: Distribution of Candidate Therapies by Phase of Development
4.7. T-Cell Immunotherapy: Target Oncological Indications
4.7.1. CAR-T Cell Immunotherapy: Popular Target Indications
4.7.2. TCR Cell Immunotherapy: Popular Target Indications
4.7.3. TIL Cell Immunotherapy: Popular Target Indications
4.8. T-Cell Immunotherapy: Key Industry Players
4.9. T-Cell Immunotherapy: Key Non-Industry Players
4.10. T-Cell Immunotherapy: Most Popular Targets for CAR-T and TCR Therapies
 
5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
5.1. Introduction
5.2. History of Development
5.3. Key Opinion Leaders
5.4. Anatomical Layout of Chimeric Antigen Receptor
5.5. Development of Chimeric Antigen Receptors
5.6. Development of CAR-T Cells
5.7. Universal CAR-Ts
5.8. Route of Administration
5.9. Toxicity Issues
5.9.1. Cytokine Release Syndrome (CRS)
5.9.2. On-Target Off-Tumor Toxicity
5.9.3. Encephalopathy and B-Cell Aplasia
5.10. Management of Toxicity Issues
5.10.1. Target Selection
5.10.2. Cell Persistence
5.10.3. Receptor Expression
5.11. CD19: An Attractive Target
5.12. Other Targets
5.13. Challenges Associated with CAR-T Therapy
5.13.1. Competitive Risks
5.13.2. Clinical Risks
5.13.3. Regulatory Risks
5.13.4. Commercial Risks
 
5.14. CTL019 (Novartis)
5.14.1. Introduction
5.14.2. History of Development
5.14.3. Development Status
5.14.4. Key Clinical Trial Results
5.14.4.1. Acute Lymphoblastic Leukemia
5.14.4.2. Non-Hodgkin’s Lymphoma
5.14.4.3. Chronic Lymphocytic Leukemia
5.14.4.4. Multiple Myeloma
5.14.5. Dosage Regimen, Treatment Cost and Manufacturing    
 
5.15. JCAR (Juno Therapeutics)
5.15.1. Introduction
5.15.2. CAR-T Design
5.15.3. Development Status
5.15.4. Key Clinical Trial Results
5.15.4.1. JCAR014
5.15.4.2. JCAR015
5.15.4.3. JCAR017
5.15.4.4. JCAR018
5.15.5. Dosage Regimen and Manufacturing
 
5.16. KTE-C19 (Kite Pharma)
5.16.1. Introduction
5.16.2. Development Status
5.16.3. Key Clinical Trial Results
5.16.3.1. Non-Hodgkin’s Lymphoma
5.16.3.2. Acute Lymphoblastic Leukemia
5.16.4. Dosage Regimen and Manufacturing
5.16.5. Next Generation eACT CAR Candidates
 
5.17. CAR-T Series (Cellular Biomedicine Group)
5.17.1. Introduction
5.17.2. History of Development
5.17.3. Development Status
5.17.4. Key Clinical Trial Results
5.17.4.1. CBM-EGFR.1
5.17.4.2. CBM-C19.1
5.17.4.3. CBM-C20.1
5.17.4.4. CBM-C30.1
5.17.5. Dosage Regimen, Manufacturing and Patent Portfolio
 
5.18. CD19 CAR (Takara Bio)
5.18.1. Introduction
5.18.2. Development Status
5.18.3. Key Clinical Trial Results
5.18.4. Dosage Regimen and Manufacturing
 
6. T-Cell Receptor (TCR) Based Therapies
6.1. Introduction
6.2. Structure of the T-Cell Receptor
6.3. Difference between CAR and TCR
6.4. History of Development
6.5. Key Opinion Leaders
6.6. Mechanism of Action
6.7. Safety Issues
6.7.1. Insertional Mutagenesis
6.7.2. On-Target Off-Tumor Toxicity and Cross-Reactivity
6.7.3. TCR Mismatch Pairing
6.8. Prerequisites of Antigen-Specific T-Cell Receptors
6.9. Identifying Strategies that Enhance Antitumor Efficacy
6.9.1. Affinity Enhanced TCRs
6.9.2. Soluble TCR Based Biologics
 
6.10. SPEAR T-Cells (Adaptimmune)
6.10.1. Introduction
6.10.1.1. NY-ESO SPEAR T-Cell
6.10.1.2. Mage-A10 T-Cell Therapy
6.10.1.3. AFP T-Cell therapy
6.10.2. History of Development
6.10.3. SPEAR T-cells Technology Platform
6.10.4. Development Status
6.10.5. Key Clinical Trial Results
6.10.5.1. Multiple Myeloma
6.10.5.2. Synovial Sarcoma
6.10.5.3. Ovarian Cancer
6.10.5.4. Multiple Myeloma, Synovial Sarcoma and Ovarian Cancer: Combined Results
6.10.6. Dosage Regimen and Manufacturing Information
 
6.11. ALT-801 (AltorBioScience)
6.11.1. Introduction
6.11.2. History of Development
6.11.3. Development Status
6.11.4. Key Clinical Trial Results
6.11.4.1. Urothelial Carcinoma
6.11.4.2. Bladder Cancer
6.11.5. Dosage Regimen and Patent Portfolio
 
6.12. IMCgp100 (Immunocore)
6.12.1. Introduction
6.12.2. Development Status
6.12.3. Key Clinical Trial Results
6.12.4. Dosage Regimen
 
6.13. JTCR016 (Juno Therapeutics)
6.13.1. Introduction
6.13.2. Development Status
6.13.3. Key Clinical Trial Results
6.13.4. Dosage Regimen
 
6.14. WT1 TCR Gene Therapy (Cell and Gene Therapy Catapult)
6.14.1. Introduction
6.14.2. History of Development
6.14.3. Development Status
6.14.4. Key Clinical Trial Results
6.14.5. Dosage Regimen and Manufacturing
 
7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies
7.1. Introduction
7.2. History of Development
7.3. Key Opinion Leaders
7.4. Research Strategies to Enhance Efficacy
7.5. A Prognostic Tool
7.6. Manufacturing Process
 
7.7. LN-144 (Lion Biotechnologies)
7.7.1. Introduction
7.7.2. Development Status
7.7.3. Key Clinical Trial Results
7.7.4. Dosage Regimen and Manufacturing 
7.7.5. Patent Portfolio
7.7.6. Next-Generation TILs
 
7.8. TIL (Nantes University Hospital)
7.8.1. Introduction
7.8.2. Development Status
7.8.3. Key Experimental Results
7.8.4. Dosage Regimen and Manufacturing 
 
7.9. TIL (Netherlands Cancer Institute)
7.9.1. Introduction
7.9.2. Development Status
7.9.3. Key Clinical Trial Results
7.9.4. Dosage Regimen and Manufacturing 
 
8. Market Opportunity
8.1. Chapter Overview
8.2. Scope and Limitations
8.3. Forecast Methodology
8.4. Overall T-Cell Immunotherapy Market(Till 2030)
8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Market
8.5.1. CTL019 (Novartis)
8.5.1.1. Target Population
8.5.1.2. Sales Forecast(Till 2030)
 
8.5.2. KTE-C19 (Kite Pharma)
8.5.2.1. Target Population
8.5.2.2. Sales Forecast (Till 2030)
 
8.5.3. JCAR015 (Juno Therapeutics)
8.5.3.1. Target Population
8.5.3.1.1. Sales Forecast(Till 2030)
8.5.4. CBM-CD30 CAR-T (Cellular Biomedicine Group)
8.5.4.1. Target Population
8.5.4.2. Sales Forecast (Till 2030)
 
8.5.5. CBM-CD20 CAR-T (Cellular Biomedicine Group)
8.5.5.1. Target Population
8.5.5.2. Sales Forecast(Till 2030)
 
8.5.6. CBM-EGFR.1 CAR-T (Cellular Biomedicine Group)
8.5.6.1. Target Population
8.5.6.2. Sales Forecast (Till 2030)
 
8.5.7. CD 19 CAR-T (Sinobioway Cell Therapy)
8.5.7.1. Target Population
8.5.7.2. Sales Forecast (Till 2030)
 
8.5.8. CD 19 CAR-T (Takara Bio)
8.5.8.1. Target Population
8.5.8.2. Sales Forecast (Till 2030)
 
8.5.9. GPC3 CAR-T (Shanghai Genechem)
8.5.9.1. Target Population
8.5.9.2. Sales Forecast (Till 2030)
 
8.5.10. JCAR017 (Juno Therapeutics)
8.5.10.1. Target Population
8.5.10.2. Sales Forecast (Till 2030)
 
8.6. Overall TCR Market (Till 2030)
8.6.1. IMCgp100 (Immunocore)
8.6.1.1. Target Population
8.6.1.2. Sales Forecast(Till 2030)
 
8.6.2. HPV-16E6-TCR (Kite Pharma)
8.6.2.1. Target Population
8.6.2.2. Sales Forecast (Till 2030)
 
8.6.3. NY-ESO-1 TCR (Adaptimmune)
8.6.3.1. Target Population
8.6.3.2. Sales Forecast(Till 2030)
 
8.6.4. HBV antigen specific TCR redirected T-Cell (Lion TCR)
8.6.4.1. Target Population
8.6.4.2. Sales Forecast(Till 2030)
 
8.6.5. ALT-801 (AltorBioScience)
8.6.5.1. Target Population
8.6.5.2. Sales Forecast(Till 2030)
 
8.6.6. JTCR016 (Juno Therapeutics)
8.6.6.1. Target Population
8.6.6.2. Sales Forecast (Till 2030)
 
8.6.7. KITE-718 (MAGE A3/A6) (Kite Pharma)
8.6.7.1. Target Population
8.6.7.2. Sales Forecast (Till 2030)
 
8.6.8. MAGE A3 (Kite Pharma)
8.6.8.1. Target Population
8.6.8.2. Sales Forecast (Till 2030)
 
8.6.9. WT-1 TCR (Cell Therapy Catapult)
8.6.9.1. Target Population
8.6.9.2. Sales Forecast(Till 2030)
 
8.6.10. MAGE A-10 TCR (Adaptimmune)
8.6.10.1. Target Population
8.6.10.2. Sales Forecast(Till 2030)
8.7. Overall TIL Therapy Market (Till 2030)
8.7.1. LN-144 (Lion Biotechnologies)
8.7.1.1. Target Population
8.7.1.2. Sales Forecast (Till 2030)
 
8.7.2. TIL Therapy (Nantes University)
8.7.2.1. Target Population
8.7.2.2. Sales Forecast (Till 2030)
 
8.7.3. TIL Therapy (Netherlands Cancer Institute)
8.7.3.1. Target Population
8.7.3.2. Sales Forecast (Till 2030)
 
9. Key Therapeutic Areas for T-Cell Therapies
9.1. Chapter Overview
9.2. Introduction
9.3. Hematological Malignancies
9.3.1. Leukemia and Lymphoma
9.3.1.1. Leukemia: Introduction and Epidemiology
9.3.1.1.1. Acute Myeloid Leukemia (AML)
9.3.1.1.2. Chronic Myeloid Leukemia (CML)
9.3.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.3.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.3.1.2. Lymphoma: Introduction and Epidemiology
9.3.1.3. Current Treatment Landscape
9.3.1.3.1. Targeted Therapies
9.3.1.4. T-Cell Immunotherapy and Research Landscape
9.3.1.4.1. CAR-Ts and Leukemia / Lymphoma
9.3.1.4.2. TCRs and Leukemia / Lymphoma
 
9.3.2. Multiple Myeloma
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. T-Cell Immunotherapy and Research Landscape
9.4. Solid Tumors
9.4.1. Metastatic Melanoma
9.4.1.1. Introduction and Epidemiology
9.4.1.2. Current Treatment Landscape
9.4.1.3. T-Cell Immunotherapy and Research Landscape
9.4.1.3.1. TILs and Metastatic Melanoma
9.4.1.3.1.1. TIL Research at the MD Anderson Cancer Center, US
9.4.1.3.1.2. TIL Research at the Sheba Medical Centre, Israel
9.4.1.3.2. TCRs and Metastatic Melanoma
9.4.1.3.3. CAR-Ts and Metastatic Melanoma
 
9.4.2. Lung Cancer
9.4.2.1. Introduction and Epidemiology
9.4.2.2. Current Treatment Landscape
9.4.2.3. T-Cell Immunotherapy and Research Landscape
 
9.4.3. Bladder Cancer
9.4.3.1. Introduction and Epidemiology
9.4.3.2. Current Treatment Landscape
9.4.3.3. T-Cell Immunotherapy and Research Landscape
 
9.4.4. Kidney Cancer
9.4.4.1. Introduction and Epidemiology
9.4.4.2. Current Treatment Landscape
9.4.4.3. T-Cell Immunotherapy and Research Landscape
 
9.4.5. Ovarian Cancer
9.4.5.1. Introduction and Epidemiology
9.4.5.2. Current Treatment Landscape
9.4.5.3. T-Cell Immunotherapy and Research Landscape
9.4.5.3.1. CAR-Ts and Ovarian Cancer
 
9.4.6. Breast Cancer
9.4.6.1. Introduction and Epidemiology
9.4.6.2. Current Treatment Landscape
9.4.6.3. T-Cell Immunotherapy and Research Landscape
9.4.6.3.1. CAR-Ts and Breast Cancer
9.4.6.3.2. TILs and Breast Cancer
 
10. Emerging Technologies
10.1. Chapter Overview
10.2. Introduction
10.3. Genome Editing Technologies: Introduction
10.4. Genome Editing Technologies: Applications
10.4.1. Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Therapies
10.4.1.1. CRISPR/Cas9 System
10.4.1.1.1. Key Components and Function
10.4.1.1.2. Mechanism of Action
10.4.1.1.3. Targeting Efficiency and Challenges
10.4.1.1.4. Next-GEN CRISPR Technology
10.4.1.1.5. Technology Providers
10.4.1.1.5.1. Editas Medicine
10.4.1.1.5.2. Intellia Therapeutics
10.4.1.1.5.3. CRISPR Therapeutics
 
10.4.1.2. TALENs
10.4.1.2.1. Structural Features
10.4.1.2.2. Mechanism of Action
10.4.1.2.3. Advantages and Challenges
10.4.1.2.4. Technology Providers
10.4.1.2.4.1. Cellectis
10.4.1.2.4.2. Editas Medicine
 
10.4.1.3. megaTAL
10.4.1.3.1. Technology Providers
10.4.1.3.1.1. bluebird bio
 
10.4.1.4. Zinc Finger Nuclease
10.4.1.4.1. Technology Providers
10.4.1.4.1.1. Sangamo Biosciences
 
10.5. Designing T-Cell Therapies with Improved Characteristics
10.5.1. Technology for Targeting Multiple Cancers
10.5.1.1. Antibody Coupled T-Cell Receptor, Unum Therapeutics
10.5.1.2. NKR-T Platform, Celyad
 
10.5.2. Technology For Improved Safety
10.5.2.1. Armored CAR, Juno Therapeutics
10.5.2.2. RheoSwitch Therapeutic System, Intrexon
10.5.2.3. Inducible Caspase 9 Safety Switch, BellicumPharmaceuticals
10.5.2.3.1. CaspaCIDe Technology
10.5.2.3.2. CIDeCAR Technology
10.5.2.3.3. GoCAR-T Technology
10.5.2.4. On-Off Switch, Multiple Companies
10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
10.5.2.4.2. On-Off Switch, Theravectys
10.5.2.5. Allogeneic Technology
10.5.2.5.1. CIK CAR-T Cells, Formula Pharmaceuticals
10.5.2.5.2. Allogeneic Platform, Celyad
10.5.2.5.3. Allogeneic Platform, Cellectis
 
11. Social Media: Emerging Trends
11.1. Chapter Overview
11.2. Trends on Twitter
11.2.1. Yearly Trends on Twitter
11.2.2. Popular Keywords on Twitter
11.2.3. Most Popular Drugson Twitter
 
12. Partnerships and Collaborations
12.1. Chapter Overview
12.2. Partnership Models
12.3. Recent Collaborations
12.3.1. Distribution of Partnerships by Year
12.3.2. Distribution of Partnerships by Type of Model
12.3.3. Leading Industry Collaborators
12.3.4. Leading Non-Industry Collaborators
12.3.5. Distribution of Partnerships by Type of Therapy
12.3.6. Distribution of Partnerships by Product Therapy
 
13. Venture Capital Support
13.1. Chapter Overview
13.2. T-Cell Immunotherapy: List of Funding Instances
13.2.1. T-Cell Immunotherapy: Funding Instances, Cumulative Number of Funding Instances by Year, pre-2009-2016
13.2.2. T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016
13.2.3. T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
13.2.4. T-Cell Immunotherapy: Funding Instances, Distribution of Amount Invested by Type of Funding
 
14. Other T-Cell Immunotherapies
14.1. Chapter Overview
14.2. Other T-Cell Immunotherapies
14.2.1. Treg Cell Therapy
14.2.1.1. Caladrius Biosciences
14.2.1.2. TxCell
14.2.1.3. TRACT Therapeutics
14.2.1.4. Other Companies
 
14.2.2. T-Cell Based Vaccines
14.2.2.1. Immunovative Therapies
14.2.2.2. Opexa Therapeutics
14.2.2.3. TVAX
 
14.2.3. Virus-Driven T-Cell Therapies
14.2.3.1. Atara Biotherapeutics
14.2.3.2. Cell Medica
14.2.3.3. Tessa Therapeutics
 
14.2.4. Fucosylation Technology Platform
14.2.4.1. Targazyme
 
14.2.5. PD-1 Knockout Engineered T-Cells
14.2.5.1. Chengdu MedGenCell
 
14.2.6. TAC-T Cells
14.2.6.1. Triumvira
 
14.2.7. Vγ9δ2 T cell T-Cell immunotherapy
14.2.7.1. GammaCell Biotechnologies
 
15. Case Study: Cell Therapy Manufacturing
15.1. Chapter Overview
15.2. Introduction
15.3. Key Challenges
15.4. Current Trends
15.4.1. Companies with In-house Capabilities
15.4.2. Contract Manufacturers
15.5. Key Considerations for a Manufacturing Site
15.6. Regulatory Landscape
 
16. T-Cell Immunotherapy: Cost Price Analysis
16.1. Chapter Overview
16.2. Cell / Gene Therapies: Factors Contributing Towards Higher Price Tags
16.3. T-Cell Immunotherapy: Pricing Models
16.3.1. Pricing Model: Based On Associated Costs
16.3.2. Pricing Model: Based On Competition
16.3.3. Pricing Model: Based on Expert Opinions
 
17. Company Profiles
17.1. Chapter Overview
17.2. Adaptimmune
17.2.1. Company Overview
17.2.2. Financial Information
17.2.3. Product Portfolio
17.2.4. Manufacturing Capabilities
17.2.5. Collaborations
17.2.5.1. Immunocore
17.2.5.2. Progenitor Cell Therapy
17.2.5.3. Thermo Fisher Scientific
17.2.5.4. GlaxoSmithKline
17.2.5.5. Universal Cells
17.2.5.6. MD Anderson Cancer Center
17.2.5.7. Merck
17.2.5.8. Bellicum Pharmaceuticals
17.2.6. Future Outlook
 
17.3. AltorBioScience
17.3.1. Company Overview
17.3.2. Financial Performance
17.3.3. Product Portfolio
17.3.4. Patent Portfolio
17.3.5. Collaborations
17.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
17.3.5.2. National Cancer Institute (NCI)
17.3.5.3. NantKwest
17.3.6. Future Outlook
 
17.4. bluebird Bio
17.4.1. Company Overview
17.4.2. Financial Performance
17.4.3. Product Portfolio
17.4.4. Collaborations
17.4.4.1. Celgene Corporation
17.4.4.2. Baylor College of Medicine
17.4.4.3. Pregenen
17.4.4.4. Five Prime Therapeutics
17.4.4.5. Kite Pharma
17.4.4.6. ViroMed
17.4.5. Future Outlook
 
17.5. Cellectis
17.5.1. Company Overview
17.5.2. Financial Information
17.5.3. Product Portfolio
17.5.4. Collaborations
17.5.4.1. Servier
17.5.4.2. CELLforCURE
17.5.4.3. Pfizer
17.5.4.4. Oncodesign
17.5.4.5. Ohio University
17.5.4.6. Weill Cornell Medical College
17.5.4.7. The University of Texas MD Anderson Cancer Center
17.5.4.8. Takara Biosciences
17.5.4.9. MabQuest
17.5.5. Future Outlook
 
17.6. Cellular Biomedicine Group
17.6.1. Company Overview
17.6.2. Financial Information
17.6.3. Product Portfolio
17.6.4. Manufacturing Capabilities
17.6.5. Collaborations
17.6.5.1. Agreen Biotech
17.6.5.2 Chinese PLA General Hospital
17.6.6. Future Outlook
 
17.7. Immunocore
17.7.1. Company Overview
17.7.2. Financial Information
17.7.3. Product Portfolio
17.7.4. Collaborations
17.7.4.1. Cardiff University
17.7.4.2. Genentech
17.7.4.3. GlaxoSmithKline
17.7.4.4. Medimmune
17.7.4.5. Eli Lilly
17.7.4.6. CMC Biologics
17.7.5. Future Outlook 
 
17.8. Juno Therapeutics
17.8.1. Company Overview
17.8.2. Financial Information
17.8.3. Product Portfolio
17.8.4. Litigations
17.8.5. Manufacturing Capabilities
17.8.6. Collaborations
17.8.6.1. Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Seattle Children’s Research Institute
17.8.6.2. Opus Bio
17.8.6.3. MedImmune/AstraZeneca
17.8.6.4. Stage Cell Therapeutics
17.8.6.5. Editas Medicine
17.8.6.6. Fate Therapeutics
17.8.6.7. X-Body
17.8.6.8. Celgene
17.8.6.9. AbVitro
17.8.6.10. Wuxi AppTec
17.8.6.11. RedoxTherapies
17.8.6.12. Eureka Therapeutics, Memorial Sloan Kettering Cancer Center
17.8.7. Future Outlook
 
17.9. Kite Pharma
17.9.1. Company Overview
17.9.2. Financial Information
17.9.3. Product Portfolio
17.9.4. Manufacturing Capabilities
17.9.5. Collaborations
17.9.5.1. National Cancer Institute / National Institutes of Health
17.9.5.2. Cabaret Biotech
17.9.5.3. NeoStem
17.9.5.4. Amgen
17.9.5.5. Tel Aviv Sourasky Medical Center
17.9.5.6. T-Cell Factory  (TCF)
17.9.5.7. bluebird bio
17.9.5.8. Leukemia and Lymphoma Society
17.9.5.9. Netherlands Cancer Institute
17.9.5.10. Alpine Immune Sciences
17.9.5.11. GE Global Research
17.9.5.12. Leiden University Medical Center
17.9.5.13. Genentech
17.9.5.14. Cell Designs Labs
17.9.5.15. University of California
17.9.5.16. BioLife Solutions
17.9.6. Future Outlook
 
17.10. Lion Biotechnologies
17.10.1. Company Overview
17.10.2. Financial Information
17.10.3. Product Portfolio
17.10.4. Manufacturing Capabilities
17.10.5. Collaborations
17.10.5.1. Lonza
17.10.5.2. H. Lee Moffitt Cancer Center and Research Institute
17.10.5.3. National Cancer Institute
17.10.5.4. National Institutes of Health
17.10.5.5. WuXiAppTec
17.10.5.6. MedImmune
17.10.5.7. PolyBioCept
17.10.5.8. Karolinska University Hospital
17.10.6. Upcoming Products: Next Generation TILs
17.10.7. Future Outlook
 
17.11. Novartis
17.11.1. Company Overview
17.11.2. Financial Information
17.11.3. Product Portfolio
17.11.4. Patent Litigation
17.11.5. Manufacturing Capabilities
17.11.6. Collaborations
17.11.6.1. University of Pennsylvania
17.11.6.2. Oxford BioMedica
17.11.6.3. Intellia Therapeutics and Caribou Biosciences
17.11.7. Future Outlook
 
17.12. Takara Bio
17.12.1. Company Overview
17.12.2. Financial Information
17.12.3. Product Portfolio
17.12.4. Manufacturing Capabilities
17.12.5. Collaborations
17.12.5.1. Tianjin Medical University, Cancer Institute and Hospital
17.12.5.2. Memorial Sloan Kettering Cancer Center
17.12.5.3. Jichi Medical University Hospital
17.12.5.4. Cellectis
17.12.5.5. Mile University School of Medicines
17.12.6. Future Outlook
 
17.13. Unum Therapeutics
17.13.1. Company Overview
17.13.2. Financial Information
17.13.3. Product Portfolio
17.13.4. Collaborations
17.13.4.1. Seattle Genetics
17.13.5. Future Outlook
 
18. Interview Transcripts
18.1. Chapter Overview
18.2. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
18.3. Peter Ho, Director, Process Development, Lion Biotechnologies
18.4. AinoKalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys
18.5. Adrian Bot, Vice President, Translational Sciences, Kite Pharma
18.6. Miguel Forte, Chief Operating Officer, TxCell
 
19. Conclusion
19.1. T-Cell Therapies Have Emerged as a Promising Segment of the Immunotherapy Market
19.2. Development Activity in the Domain is Led by Academic Institutes, Some of Which Have Collaborated with Industry Players
19.3. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
19.4. A Number of Novel Technological Platforms Have Emerged as Vital Enablers of Growth In This Market
19.5. A Significant Number of Strategic Alliances Have Been Forged in Order To Advance the Development of Different Product Candidates
19.6. Manufacturing Complexities and High Development Cost of These Therapies Necessitate Premium Pricing
19.7. Multiple Novel Types of Immunotherapies, Other Than CAR-T, TCR and TIL, are Expected to Emerge in The Mid-Long Run
19.8. Backed by a Progressive Pipeline and VC Support, the Market is Poised for Significant Growth
 
20. Appendix 1: Tabulated Data
 
21. Appendix 2: List of Companies and Organizations
 
 
 
Figure 3.1 The Four Pillars of Cancer Therapy
 
Figure 3.2 Difference between Active and Passive Immunotherapies
 
Figure 3.3 Difference between Specific and Non-Specific Immunotherapies
 
Figure 3.4 3Es of the Immune System
 
Figure 3.5 Strategies Employed for the Redirection of T-Cells
 
Figure 3.6 T-Cell Immunotherapy: Target Therapeutic Areas
 
Figure 3.7 T-Cell Immunotherapy: Key Challenges
 
Figure 4.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
 
Figure 4.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
 
Figure 4.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
 
Figure 4.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
 
Figure 4.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
 
Figure 4.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
 
Figure 4.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
 
Figure 4.8 T-Cell Immunotherapy Pipeline: Popular Target Indications
 
Figure 4.9 CAR-T Cell Immunotherapy: Popular Target Indications
 
Figure 4.10 TCR Cell Immunotherapy: Popular Target Indications
 
Figure 4.11 TIL Cell Immunotherapy: Popular Target Indications
 
Figure 4.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
 
Figure 4.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
 
Figure 4.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
 
Figure 4.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
 
Figure 4.16 TCR Therapy Pipeline: Distribution by Target Antigen
 
Figure 5.1 Historical Timeline: Development of CAR-T cells
 
Figure 5.2 CAR-T Cell Therapy: Geographical Distribution of Key Opinion Leaders
 
Figure 5.3 CAR-T: Structure and Domains
 
Figure 5.4 CAR-T: CAR Generations Layout
 
Figure 5.5 Development of CAR-T Cells
 
Figure 5.6 Challenges Associated with CAR-T Therapy
 
Figure 5.7 CTL019: Industry Sponsored Clinical Trial Design
 
Figure 5.8 CTL019: Non-Industry Sponsored Clinical Trial Design
 
Figure 5.9 JCAR Series: Industry Sponsored Clinical Trial Design
 
Figure 5.10 JCAR Series: Non-Industry Sponsored Clinical Trial Design
 
Figure 5.11 KTE-C19: Clinical Trial Design
 
Figure 5.12 Manufacturing of CD19 CAR-T Cells: Process Comparison
 
Figure 5.13 Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
 
Figure 5.14 Takara Bio’s CD19 CAR-T: Clinical Trial Design
 
Figure 6.1 TCR Cell Therapy: Geographical Distribution of Key Opinion Leaders
 
Figure 6.2 TCR Cell Therapy: Development Process
 
Figure 6.3 NY-ESO TCR: Industry Sponsored Clinical Trial Design
 
Figure 6.4 MAGE A-10 TCR: Industry Sponsored Clinical Trial Design
 
Figure 6.5 ALT-801: Clinical Trial Design
 
Figure 6.6 IMCgp100: Clinical Trial Design
 
Figure 6.7 JTCR016: Clinical Trial Design
 
Figure 6.8 WT1 TCR: Clinical Trial Design
 
Figure 7.1 TIL Cell Therapy: Geographical Distribution of Key Opinion Leaders
 
Figure 7.2 TIL Cell Therapy: Manufacturing Process
 
Figure 7.3 LN-144: Clinical Trial Design
 
Figure 7.4 Nantes University Hospital’s TIL Therapy: Clinical Trial Design
 
Figure 7.5 Nantes University Hospital’s TIL Therapy: Production Procedure
 
Figure 7.6 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Design
 
Figure 8.1 Overall T-Cell Immunotherapy Market (Till 2030): Base Scenario (USD Billion)
 
Figure 8.2 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
 
Figure 8.3 Overall CAR-T Market Forecast(Till 2030): Base Scenario (USD Billion)
 
Figure 8.4 CTL019: Current Status by Highest Phase of Development
 
Figure 8.5 CTL019 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.6 KTE-C19: Current Status by Highest Phase of Development
 
Figure 8.7 KTE-C19 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.8 JCAR015 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.9 CBM-CD30 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.10 CBM-CD20 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.11 CBM-EGFR CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.12 Sinobioway Cell Therapy’s CD 19 CAR-T: Current Status by Highest Phase of Development
 
Figure 8.13 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.14 Takara Bio’s CD 19 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.15 GPC3 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 8.16 JCAR017 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.17 Overall TCR Market Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.18 IMCgp100 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 8.19 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 8.20 NY-ESO-1 TCR: Current Status by Highest Phase of Development
 
Figure 8.21 NY-ESO-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.22 HBV antigen specific TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.23 ALT-801: Current Status by Highest Phase of Development
 
Figure 8.24 ALT-801 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.25 JTCR016: Current Status by Highest Phase of Development
 
Figure 8.26 JTCR016 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.27 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 8.28 MAGE A3 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.29 WT-1 TCR: Current Status by Highest Phase of Development
 
Figure 8.30 WT-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.31 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 8.32 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
 
Figure 8.33 LN-144 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.34 TIL Therapy (Nantes University) Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 8.35 TIL Therapy (Netherlands Cancer Institute) Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Figure 9.1 Leukemia: Classification
 
Figure 9.2 Leukemia: Global Epidemiological Distribution
 
Figure 9.3 Lymphoma: Global Epidemiological Distribution
 
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
 
Figure 9.5 Melanoma: Global Epidemiological Distribution
 
Figure 9.6 Lung Cancer: Classification
 
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
 
Figure 9.8 Bladder Cancer: Global Epidemiological Distribution
 
Figure 9.9 Kidney Cancer: Global Epidemiological Distribution
 
Figure 9.10 Ovarian Cancer: Global Epidemiological Distribution
 
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
 
Figure 10.1 Genome Editing Technologies: Applications
 
Figure 10.2 Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Platforms
 
Figure 10.3 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
 
Figure 10.4 Properties of Enhanced T-Cell Platform
 
Figure 10.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
 
Figure 11.1 T-Cell Immunotherapy Social Media Analysis: Twitter Trends, January 2011-June2016
 
Figure 11.2 T-Cell Immunotherapy Social Media Analysis: Highlights on Twitter, January 2011 - June 2016
 
Figure 11.3 T-Cell Immunotherapy Social Media Analysis: Twitter, Most Popular Candidates, January 2011-June 2016
 
Figure 12.1 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
 
Figure 12.2 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model 
 
Figure 12.3 T-Cell Immunotherapy: Leading Industry Collaborators
 
Figure 12.4 T-Cell Immunotherapy: Leading Non-industry Collaborators
 
Figure 12.5 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
 
Figure 12.6 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
 
Figure 13.1 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
 
Figure 13.2 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
 
Figure 13.3 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
 
Figure 13.4 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
 
Figure 14.1 Treg Cells: Functions
 
Figure 15.1 Cell Therapy Manufacturing: Key Steps
 
Figure 15.2 Cell Therapy Manufacturing: Scenarios
 
Figure 15.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
 
Figure 17.1 Adaptimmune: Funding Instances (USD Million)
 
Figure 17.2 Altor Bioscience: Funding Instances (USD Million)
 
Figure 17.3 bluebird bio: Funding Instances (USD Million)
 
Figure 17.4 Cellectis: Funding Instances (USD Million)
 
Figure 17.5 CBMG: Funding Instances (USD Million)
 
Figure 17.6 Immunocore: Funding Instances (USD Million)
 
Figure 17.7 Juno Therapeutics: Funding Instances (USD Million)
 
Figure 17.8 Kite Pharma: Funding Instances (USD Million)
 
Figure 17.9 Lion Biotechnologies: Funding Instances (USD Million)
 
Figure 17.10 Novartis: Revenues 2011-9M 2016 (USD Billion)
 
Figure 17.11 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
 
Figure 17.12 Takara Bio: Revenues, 2011-2016 (JPY Billion)
 
Figure 17.13 Unum Therapeutics: Funding Instances (USD Million)
 
Figure 17.14 ACTR Technology: Treatment Process
 
Figure 19.1 T-Cell Immunotherapy Market Landscape: Industry Participants
 
Figure 19.2 T-Cell Immunotherapy Market Landscape: Non-industry Participants
 
Figure19.3 T-Cell Immunotherapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Million)
 
 
 
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
 
Table 3.2 Retroviral Vectors: Salient Features
 
Table 3.3 Lentiviral Vectors: Salient Features
 
Table 4.1 CAR-T Cell Immunotherapy: Clinical Pipeline
 
Table 4.2 CAR-T Cell Immunotherapy: Preclinical / Discovery Pipeline
 
Table 4.3 TCR Cell Therapy: Clinical Pipeline
 
Table 4.4 TCR Cell Immunotherapy: Preclinical / Discovery Pipeline
 
Table 4.5 TIL Cell Immunotherapy: Clinical Pipeline
 
Table 4.6 TIL Cell Immunotherapy: Preclinical / Discovery Pipeline
 
Table 5.1 Key Characteristics of CAR-T cells
 
Table 5.2 Comparison Between 1st and 2nd Generation CARs
 
Table 5.3 Grading Criteria for CRS
 
Table 5.4 Safety Switches under Development for CART-T Therapy
 
Table 5.5 CD19 CAR-T Cells: Preclinical Results
 
Table 5.6 Other Targets under Clinical/Preclinical Studies for CAR-T Therapy
 
Table 5.7 CTL019: Clinical Studies
 
Table 5.8 CTL019: Clinical Trial Endpoints (ALL)
 
Table 5.9 CTL019: Clinical Trial Endpoints (CLL/MM/NHL)
 
Table 5.10 JCAR Series: Molecules in Clinical Development
 
Table 5.11 JCAR: CAR-T Design
 
Table 5.12 JCAR014: Current Status of Development
 
Table 5.13 JCAR015: Current Status of Development
 
Table 5.14 JCAR017: Current Status of Development
 
Table 5.15 JCAR018: Current Status of Development
 
Table 5.16 JCAR020: Current Status of Development
 
Table 5.17 JCAR023: Current Status of Development
 
Table 5.18 JCAR024: Current Status of Development
 
Table 5.19 JCAR Series: Clinical Trial Endpoints (Phase II)
 
Table 5.20 JCAR Series: Clinical Trial Endpoints (Phase I)
 
Table 5.21 JCAR: Dosage Regimen
 
Table 5.22 KTE-C19: Clinical Studies
 
Table 5.23 KTE-C19: Clinical Trial Endpoints
 
Table 5.24 KTE-C19: ZUMA-1 Phase II Results (≥3 months Follow-Up)
 
Table 5.25 KTE-C19: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
 
Table 5.26 CBM CAR-T Series: Clinical Products, 
 
Table 5.27 CBM-CD19.1 CAR-T: Clinical Studies
 
Table 5.28 CBM-CD20 CAR-T: Clinical Status
 
Table 5.29 CBM-CD30.1 CAR-T: Clinical Status
 
Table 5.30 CBM-EGFR.1 CAR-T: Clinical Status
 
Table 5.31 Cellular Biomedicine’s CAR-T Series: Clinical Trial Endpoints
 
Table 5.32 CBM CAR-T Series: Patent Portfolio
 
Table 5.33 Takara Bio’s CD19 CAR-T: Current Status of Development
 
Table 5.34 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
 
Table 6.1 CAR-T Cell and TCR Based Therapies: Key Differences
 
Table 6.2 NY-ESO TCR: Clinical Studies
 
Table 6.3 MAGE-A10: Clinical Studies
 
Table 6.4 NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
 
Table 6.5 ALT-801: Clinical Studies
 
Table 6.6 ALT-801: Clinical Trial Endpoints
 
Table 6.7 IMCgp100: Clinical Studies
 
Table 6.8 IMCgp100: Clinical Trial Endpoints
 
Table 6.9 JTCR016: Clinical Studies
 
Table 6.10 JTCR016: Clinical Trial Endpoints
 
Table 6.11 WT1 TCR: Clinical Studies
 
Table 6.12 WT1 TCR: Clinical Trial Endpoints
 
Table 7.1 LN-144: Clinical Trial Endpoints
 
Table 7.2 LN-144: Patent Portfolio
 
Table 7.3 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
 
Table 7.4 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
 
Table 8.1 T-Cell Immunotherapy: List of Forecasted Molecules
 
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
 
Table 9.2 Comparison of Marketed Targeted Therapeutics: Leukemia
 
Table 9.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
 
Table 9.4 T-Cell Immunotherapy: Targets under Investigation for Leukaemia
 
Table 9.5 T-Cell Immunotherapy: Targets under Investigation for Lymphoma
 
Table 9.6 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
 
Table 9.7 T-Cell Immunotherapy: Targets under Investigation for Multiple Myeloma
 
Table 9.8 Comparison of Marketed Targeted Therapeutics: Melanoma
 
Table 9.9 TIL Therapy: Historical Development of Treatment Protocols at the National Cancer Institute
 
Table 9.10 Comparison of Marketed Therapeutics: Lung Cancer
 
Table 9.11 T-Cell Immunotherapy: Targets under Investigation for Lung Cancer
 
Table 9.12 Comparison of Marketed Targeted Therapeutics: Renal Cell Carcinoma
 
Table 9.13 T-Cell Immunotherapy: Targets under Investigation for Ovarian Cancer
 
Table 9.14 Comparison of Marketed Therapeutics: Breast Cancer
 
Table 9.15 T-Cell Immunotherapy: Targets under Investigation for Breast Cancer
 
Table 10.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
 
Table 10.2 Editas Medicine: Funding Instances
 
Table 10.3 Editas Medicine: Collaborations
 
Table 10.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
 
Table 10.5 Intellia Therapeutics: Funding Instances
 
Table 10.6 Intellia Therapeutics: Collaborations
 
Table 10.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
 
Table 10.8 CRISPR Therapeutics: Funding Instances
 
Table 10.9 CRISPR Therapeutics: Collaborations
 
Table 10.10 Cellectis: Funding Instances
 
Table 10.11 Cellectis: Collaborations
 
Table 10.12 bluebird bio: Funding Instances
 
Table 10.13 bluebird bio: Collaborations
 
Table 10.14 Sangamo Biosciences: Funding Instances
 
Table 10.15 Sangamo Biosciences: Collaborations
 
Table 10.16 Unum Therapeutics: Funding Instances
 
Table 10.17 Unum Therapeutics: Collaborations
 
Table 10.18 Celyad: Funding Instances
 
Table 10.19 Celyad: Collaborations
 
Table 10.20 Intrexon: Funding Instances
 
Table 10.21 Intrexon: Collaborations
 
Table 10.22 Bellicum Pharmaceuticals: Key Switch Technologies
 
Table 10.23 Bellicum Pharmaceuticals: Switch Technologies, Research Publications 
 
Table 10.24 Bellicum Pharmaceuticals: Funding Instances
 
Table 10.25 Bellicum Pharmaceuticals: Collaborations
 
Table 10.26 Theravectys: Funding Instances
 
Table 10.27 Formula Pharmaceuticals: Collaborations
 
Table 12.1 T-Cell Immunotherapy: Recent Collaborations
 
Table13.1 T-Cell Immunotherapy: List of Funding Rounds / Grants and Investors Involved
 
Table 14.1 List of Other Novel T-Cell Immunotherapies
 
Table 14.2 Treg Cell: Properties
 
Table 15.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
 
Table 15.2 Cell Therapy Manufacturing: Contract Manufacturers
 
Table 16.1 Marketed Cell / Gene Therapies: Price
 
Table 16.2 Marketed Targeted Drugs for Cancer: Price
 
Table 16.3 T-Cell Immunotherapy: Expert Opinions on Pricing
 
Table 17.1 Adaptimmune: T-Cell Immunotherapy Pipeline
 
Table 17.2 Adaptimmune: T-Cell Immunotherapy Collaborations
 
Table 17.3 AltorBioScience: T-Cell Immunotherapy Pipeline
 
Table 17.4 AltorBioScience: T-Cell Immunotherapy Collaborations
 
Table 17.5 bluebird bio: T-Cell Immunotherapy Pipeline
 
Table 17.6 bluebird bio: T-Cell Immunotherapy Collaborations
 
Table 17.7 Cellectis: T-Cell Immunotherapy Pipeline
 
Table 17.8 Cellectis: T-Cell Immunotherapy Collaborations
 
Table 17.9 Cellular Biomedicine Group: T-Cell Immunotherapy Pipeline
 
Table 17.10 Cellular Biomedicine Group: T-Cell Immunotherapy Collaborations
 
Table 17.11 Immunocore: T-Cell Immunotherapy Pipeline
 
Table 17.12 Immunocore: T-Cell Immunotherapy Collaborations
 
Table 17.13 Juno Therapeutics: T-Cell Immunotherapy Pipeline
 
Table 17.14 Juno Therapeutics: T-Cell Immunotherapy Collaborations
 
Table 17.15 Kite Pharma: T-Cell Immunotherapy Pipeline
 
Table 17.16 Kite Pharma: T-Cell Immunotherapy Collaborations
 
Table 17.17 Lion Biotechnologies: T-Cell Immunotherapy Pipeline
 
Table 17.18 Lion Biotechnologies: T-Cell Immunotherapy Collaborations
 
Table 17.19 Novartis: T-Cell Immunotherapy Pipeline
 
Table 17.20 Novartis: T-Cell Immunotherapy Collaborations
 
Table 17.21 Takara Bio: T-Cell Immunotherapy Pipeline
 
Table 17.22 Takara Bio: T-Cell Immunotherapy Collaborations
 
Table 17.23 Unum Therapeutics: T-Cell Immunotherapy Pipeline
 
Table 17.24 Unum Therapeutics: T-Cell Immunotherapy Collaborations
 
Table 20.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
 
Table 20.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
 
Table 20.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
 
Table 20.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
 
Table 20.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
 
Table 20.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
 
Table 20.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
 
Table 20.8 T-Cell Immunotherapy: Popular Target Indications
 
Table 20.9 CAR-T Cell Immunotherapy: Popular Target Indications
 
Table 20.10 TCR Cell Immunotherapy: Popular Target Indications
 
Table 20.11 TIL Cell Immunotherapy: Popular Target Indications
 
Table 20.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
 
Table 20.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
 
Table 20.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
 
Table 20.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
 
Table 20.16 TCR Therapy Pipeline: Distribution by Target Antigen
 
Table 20.17 Overall T-Cell Immunotherapy Market (Till 2030): Conservative Scenario (USD Billion)
 
Table 20.18 Overall T-Cell Immunotherapy Market(Till 2030): Base Scenario (USD Billion)
 
Table 20.19 Overall T-Cell Immunotherapy Market(Till 2030): Optimistic Scenario (USD Billion)
 
Table 20.20 T-Cell Therapy Market, 2020, 2025 and 2030: Conservative Scenario (USD Million)
 
Table 20.21 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
 
Table 20.22 T-Cell Therapy Market, 2020, 2025 and 2030: Optimistic Scenario (USD Million)
 
Table 20.23 Overall CAR-T Market Forecast(Till 2030): Conservative Scenario (USD Billion)
 
Table 20.24 Overall CAR-T Market Forecast (Till 2030): Base Scenario (USD Billion)
 
Table 20.25 Overall CAR-T Market Forecast (Till 2030): Optimistic Scenario (USD Billion)
 
Table 20.26 CTL019 Sales Forecast(Till 2030): Conservative Scenario (USD Million
 
Table 20.27 CTL019 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.28 CTL019 Sales Forecast(Till 2030): Optimistic Scenario (USD Million
 
Table 20.29 KTE-C19 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.30 KTE-C19 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.31 KTE-C19 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.32 JCAR015 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.33 JCAR015 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.34 JCAR015 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.35 CBM-CD30 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.36 CBM-CD30 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.37 CBM-CD30 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.38 CBM-CD20 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.39 CBM-CD20 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.40 CBM-CD20 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.41 CBM-EGFR CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.42 CBM-EGFR CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.43 CBM-EGFR CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.44 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.45 Sinobioway Cell Therapy’s CD 19CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.46 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.47 Takara Bio’s CD 19 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.48 Takara Bio’s CD 19CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.49 Takara Bio’s CD 19 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.50 GPC3 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.51 GPC3 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.52 GPC3 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.53 JCAR017 Sales Forecast, (Till 2030): Conservative Scenario (USD Million)
 
Table 20.54 JCAR017 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.55 JCAR017 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.56 Overall TCR Market Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.57 Overall TCR Market Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.58 Overall TCR Market Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.59 IMCgp100 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.60 IMCgp100 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.61 IMCgp100 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.62 HPV-16E6-TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.63 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.64 HPV-16E6-TCR Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.65 NY-ESO-1 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.66 NY-ESO-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.67 NY-ESO-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.68 HBV antigen specific TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.69 HBV antigen specific TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.70 HBV antigen specific TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.71 ALT-801 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.72 ALT-801 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.73 ALT-801 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.74 JTCR016 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.75 JTCR016 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.76 JTCR016 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.77 KITE-718 (MAGE A3/A6) Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.78 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.79 KITE-718 (MAGE A3/A6) Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.80 MAGE A3 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.81 MAGE A3 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.82 MAGE A3 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.83 WT-1 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.84 WT-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.85 WT-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.86 MAGE A-10 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.87 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.88 MAGE A-10 TCR Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.89 Overall TIL Market Forecast(Till 2030): Conservative Scenario (USD Billion)
 
Table 20.90 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
 
Table 20.91 Overall TIL Market Forecast(Till 2030): Optimistic Scenario (USD Billion)
 
Table 20.92 LN-144 Sales Market Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.93 LN-144 Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.94 LN-144 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
 
Table 20.95 Nantes University Hospital’s TIL Therapy Sales Forecast(Till 2030): Conservative Scenario (USD Million)
 
Table 20.96 Nantes University Hospital’s TIL Therapy Sales Forecast(Till 2030): Base Scenario (USD Million)
 
Table 20.97 Nantes University Hospital’s TIL Therapy Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.98 Netherland Cancer Institute’s TIL Therapy Sales Market Forecast, 2018-2030: Conservative Scenario (USD Million)
 
Table 20.99 Netherland Cancer Institute’s TIL Therapy Sales Forecast, 2018-2030: Base Scenario (USD Million)
 
Table 20.100 Netherland Cancer Institute’s TIL Therapy Sales Forecast, 2018-2030: Optimistic Scenario (USD Million)
 
Table 20.101 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
 
Table 20.102 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
 
Table 20.103 T-cell Immunotherapy: Leading Industry Collaborators
 
Table 20.104 T-cell immunotherapy: Leading Non-industry Collaborators
 
Table 20.105 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
 
Table 20.106 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
 
Table 20.107 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
 
Table 20.108 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
 
Table 20.109 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
 
Table 20.110 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
 
Table 20.111 Adaptimmune: Funding Instances (USD Million)
 
Table 20.112 AltorBioScience: Funding Instances (USD Million)
 
Table 20.113 blubird bio: Funding Instances (USD Million)
 
Table 20.114 Cellectis: Funding Instances (USD Million)
 
Table 20.115 Cellular Biomedicine Group: Funding Instances (USD Million)
 
Table 20.116 Immunocore: Funding Instances (USD Million)
 
Table 20.117 Juno Therapeutics: Funding Instances (USD Million)
 
Table 20.118 Kite Pharma: Funding Instances (USD Million)
 
Table 20.119 Lion Biotechnologies: Funding Instances (USD Million)
 
Table 20.120 Novartis: Revenues 2011-9M 2016 (USD Billion)
 
Table 20.121 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
 
Table 20.122 Takara Bio: Revenues, 2011-2016 (JPY Million)
 
Table 20.123 Unum Therapeutics: Funding Instances (USD Million)
 
Table 20.124 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
 
 
 
The following companies and organizations have been mentioned in the report.
 
  1. AbbVie
  2. Abingworth
  3. AbraxisBioScience
  4. AbVitro
  5. Adaptimmune
  6. Adicet Bio
  7. Advanced BioScience Laboratories
  8. Adverum Biotechnologies
  9. Affiliated Hospital to Academy of Military Medical Sciences
  10. AGF Private Equity
  11. AgonOx
  12. Agreen Biotech 
  13. AJU IB Investment 
  14. Alaska Permanent Fund
  15. Albert Einstein College of Medicine 
  16. Alexandria Ventures 
  17. Alexion Pharmaceuticals
  18. Allen Laboratories
  19. Allos Therapeutics
  20. Alpine Immune Sciences
  21. Alta Partners
  22. AltorBioScience
  23. Amgen
  24. Amsterdam BioTherapeutics Unit 
  25. Antoni van Leeuwenhoek Hospital 
  26. apcethBiopharma
  27. Aquilo Capital Management
  28. ARCH Venture Partners 
  29. Argos Therapeutics
  30. ArtaxBioPharma
  31. Astellas Pharma
  32. AstraZeneca
  33. Asymptote 
  34. Atara Biotherapeutics
  35. Atlantic Bio GMP
  36. Atlas Venture
  37. Atreca Therapeutics 
  38. AURORA BioPharma
  39. Autolus
  40. AVG Ventures
  41. Avidex
  42. BankInvest Biomedical Venture
  43. Batavia Biosciences  
  44. Bavarian Nordic
  45. Baxalta
  46. Bayer
  47. Bayer Crop Sciences
  48. Baylor College of Medicine
  49. Beijing Doing Biomedical
  50. Bellicum Pharmaceuticals
  51. Bezos Expeditions
  52. Bill & Melinda Gates Foundation
  53. Bio Elpida
  54. Biogen
  55. BioLife Solutions
  56. Biomedical Catalyst 
  57. Biomedical Catalyst Fund
  58. BioNTech
  59. Biotecnol
  60. BioVeda China Fund 
  61. bluebird bio
  62. Boehringer Ingelheim
  63. Boston Children's Hospital 
  64. Bpifrance
  65. Brace Pharma Capital
  66. Breast International Group
  67. Bristol-Myers Squibb
  68. Broad Institute
  69. Broadfin Capital
  70. Cabaret Biotech
  71. Caladrius Biosciences
  72. California Institute for Regenerative Medicine
  73. Cancer Prevention and Research Institute of Texas
  74. Cancer Research UK
  75. Cardiff University
  76. Caribou Biosciences
  77. CARsgen Therapeutics
  78. Cartherics
  79. Casdin Capital
  80. Celgene
  81. Cell and Gene Therapy Catapult 
  82. Cell Design Labs
  83. Cell Medica
  84. Cell Therapies
  85. Cell Therapy and Cell Engineering Facility
  86. Cellectis
  87. CELLforCURE
  88. Cellular Biomedicine Group
  89. Cellular Therapeutics
  90. Celyad
  91. Centre for Cell Manufacturing Ireland
  92. Changzheng Hospital
  93. Charité - Universitätsmedizin Berlin
  94. CHDI Foundation
  95. Chengdu MedGenCell
  96. Children's Hospital of Philadelphia 
  97. Children's Mercy Hospital Kansas City
  98. Chimeric Therapeutics
  99. Chinese PLA General Hospital
  100. Christie NHS Foundation Trust
  101. Chugai Seiyaku Kabushiki Kaisha
  102. City of Hope Medical Center
  103. Clough Capital Partners 
  104. Cognate Bioservices
  105. Cold Genesys
  106. Columbia University
  107. Cooperative Research Center for Cell Therapy Manufacturing
  108. Corixa
  109. Cowen Group Investment
  110. CRISPR Therapeutics
  111. Cystic Fibrosis Foundation Therapeutics
  112. Cytolumina Technologies
  113. Cytovance Biologics
  114. Dana-Farber Cancer Institute
  115. Dangdai International
  116. Dartmouth College
  117. Deerfield Management
  118. Delenex Therapeutics 
  119. Dendreon
  120. Duke University
  121. Dutch Cancer Society 
  122. Easton Capital
  123. EcoR1 Capital
  124. Editas Medicine 
  125. Edmond Venture Capital
  126. Eisai
  127. Eli Lilly 
  128. Endocyte
  129. Erasmus University Medical Center
  130. ERS Genomics
  131. EUFETS 
  132. Eureka Therapeutics
  133. Fate Therapeutics 
  134. FCB-Pharmicell
  135. Fetolumina Technologies 
  136. FGP Capital 
  137. Fidelity Biosciences
  138. Fidelity Management & Research Company
  139. Financière IDAT 
  140. Finnish Innovation Fund
  141. Five Prime Therapeutics 
  142. Flagship Ventures
  143. Fondazione Telethon
  144. Forbion Capital Partners
  145. Foresite Capital
  146. Formula Pharmaceuticals
  147. Fortress Biotech
  148. Franklin Templeton Investments
  149. FraunhoferInsitute for Cell Therapy and Immunology
  150. Fred Hutchinson Cancer Research Center
  151. Fuda Cancer Hospital
  152. Gadeta
  153. GammaCell Bio-Technologies
  154. GE Global Research
  155. Gene and Cell Therapy Lab
  156. Genentech 
  157. Généthon
  158. GigaGen
  159. Gilead Sciences
  160. GlaxoSmithKline
  161. Google Ventures
  162. Great Ormond Street Hospital 
  163. Green Cross Cell
  164. Griffin Securities
  165. Guy's and St Thomas' NHS Foundation Trust
  166. H. Lee Moffitt Cancer Center and Research Institute Hospital
  167. Hadassah Medical Organization
  168. Harvard University
  169. Heat Biologics
  170. Herlev Hospital
  171. Howard Hughes Medical Institute
  172. iCarTABBioMed
  173. iCell Therapeutics 
  174. ImClone Systems
  175. Immatics
  176. Immune Therapeutics
  177. Immunex
  178. ImmunoCellular Therapeutics
  179. Immunocore
  180. Immunovative Therapies
  181. Imperial College London
  182. Imperial Innovations
  183. Innovative Cellular Therapeutics
  184. Innovative Genome Initiative 
  185. Institut Curie (Curie Institute)
  186. Institut Pasteur (Pasteur Institute)
  187. Institute of Translational Health Sciences
  188. Intellia Therapeutics 
  189. Intrexon
  190. Iowa State University
  191. Janssen Biotech
  192. Janus Capital Group
  193. JCR Pharmaceutical
  194. Jennison Associates
  195. JIC GenesisFountain Healthcare Ventures
  196. Jichi Medical University Hospital
  197. JMP Securities
  198. John Wayne Cancer Institute
  199. Johns Hopkins Kimmel Cancer Center
  200. Johns Hopkins University
  201. Johnson & Johnson
  202. Jolly Innovation Ventures
  203. Juno Therapeutics 
  204. JW Biotechnology
  205. Kaitai Capital
  206. Karolinska University Hospital
  207. Keio University School of Medicine
  208. Khosla Ventures
  209. King's College London- Rayne Cell Therapy Suite 
  210. Kite Pharma
  211. KTB Ventures
  212. Leiden University Medical Center
  213. Leucid Bio
  214. Lifeline Ventures Fund
  215. Ligand Pharmaceuticals 
  216. Lilly Asia Ventures
  217. Lion Biotechnologies
  218. Lion TCR
  219. Lonza Biologics
  220. Loyola University
  221. Lymphoma and Leukemia Society
  222. MabQuest
  223. Malin Corporation
  224. Massachusetts General Hospital
  225. MaSTherCell
  226. Max DelbrückCenter for Molecular Medicine
  227. MaxCyte
  228. Mayo Clinic 
  229. MD Anderson Cancer Center
  230. Medarex
  231. Medicxi Ventures
  232. Medigene
  233. MedImmune
  234. MedPost Urgent Care
  235. Memorial Sloan Kettering Cancer Center
  236. Merck 
  237. Merck Serono
  238. Merlin Nexus
  239. Mie University
  240. Millennium Pharmaceuticals
  241. MiltenyiBiotec
  242. Mission Bay Capital
  243. Molecular and Cellular Therapeutics
  244. MolMed
  245. Morphotek
  246. Mustang Bio
  247. Nantes University Hospital
  248. NantKwest (earlier Conkwest)
  249. NantWorks
  250. National Cancer Institute
  251. National Institute of Allergy and Infectious Diseases
  252. National Institutes of Health
  253. National University of Ireland
  254. National University of Singapore
  255. Netherlands Cancer Institute
  256. New Enterprise Associates
  257. New Leaf Venture Partners
  258. New River Management
  259. NewVa Capital Partners
  260. NIHR Oxford Biomedical Research Centre
  261. Novartis
  262. Novartis Venture Fund
  263. Novo Ventures
  264. Oberland Capital 
  265. ODYSSEE Venture
  266. Ohio State University
  267. Omega Funds
  268. Oncodesign Biotechnology
  269. OnCyte
  270. ONO Pharmaceutical
  271. Onyx Pharmaceuticals   
  272. Opexa Therapeutics
  273. Opus Bio 
  274. OrbiMed
  275. OSEO 
  276. OspedalePediatrico Bambino Gesù (Bambino Gesù Children’s Hospital)
  277. Ospedale San Raffaele (San Raffaele Hospital)
  278. Oxford BioMedica
  279. Partners Innovation Fund
  280. Peking University
  281. Perceptive Bioscience Investments
  282. PersonGen Biomedicine (Suzhou)
  283. Peter MacCallum Cancer Centre
  284. Pfizer 
  285. PharmaCell
  286. Pharmacyclics
  287. Pierre Fabre Group
  288. PLA General Hospital
  289. Polaris Partners
  290. PolyBioCept
  291. Pontifax
  292. Poseida Therapeutics
  293. Precision BioSciences
  294. Pregenen
  295. Progenitor Cell Therapy
  296. Prometheus Laboratories
  297. QueensBridge Venture Partners
  298. Quogue Capital 
  299. QVT Financial
  300. RA Capital Management
  301. Ramius Capital Group
  302. Redmile Group
  303. RedoxTherapies
  304. Regeneron Pharmaceuticals
  305. Remeditex Ventures
  306. Renji Hospital
  307. Ridgeback Capital Management
  308. Ridgeway Capital Partners
  309. Riverbank Capital Securities
  310. Roche
  311. Rock Springs Capital
  312. Rockland Immunochemicals
  313. Roger Williams Medical Center
  314. Roswell Park Cancer Institute
  315. Royal Adelaide Hospital Cancer Center
  316. Sabby Management
  317. Sanford Research
  318. SangamoBioSciences
  319. Sanofi Aventis
  320. Sanofi-Genzyme BioVentures
  321. Schering-Plough
  322. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
  323. Seattle Children’s Hospital 
  324. Seattle Genetics
  325. Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  326. Second Military Medical University
  327. Sectoral Asset Management
  328. Servier
  329. Shanghai Cancer Institute 
  330. Shanghai Chest Hospital
  331. Shanghai Genechem
  332. Sheba Medical Center
  333. Shenzhen Institute for Innovation and Translational Medicine
  334. Shenzhen Second People's Hospital
  335. Shionogi
  336. Sichuan University 
  337. Sidney Kimmel Comprehensive Cancer Center
  338. Sinobioway Cell Therapy
  339. SOLTI Breast Cancer Research Group
  340. Sorrento Therapeutics
  341. SOTIO
  342. Southwest Hospital
  343. Spectrum Pharmaceuticals
  344. SR One
  345. St. Jude Children's Research Hospital
  346. Stage Cell Therapeutics 
  347. Stanford University
  348. Stifel
  349. Sun Yat-Sen University
  350. Super-T Cell Cancer Company
  351. Syncona
  352. T. Rowe Price Associates
  353. Takara Biosciences
  354. Targazyme
  355. T-Cell Factory
  356. Techno Venture Management
  357. Tel Aviv Sourasky Medical Center
  358. Terumo
  359. Tessa Therapeutics
  360. Tethys Holdings
  361. Texas Emerging Technology Fund
  362. The Clinical Cell and Vaccine Production Facility
  363. Theravectys
  364. Thermo Fisher Scientific 
  365. Third Military Medical University
  366. Third Rock Ventures
  367. Third Security
  368. Three Arch Opportunity Fund
  369. Tianjin Medical University Cancer Institute and Hospital
  370. TiGenix
  371. TILT Biotherapeutics 
  372. Tmunity Therapeutics
  373. TNK Therapeutics 
  374. Tongji Hospital
  375. Tongji University School of Medicine
  376. TRACT Therapeutics
  377. Transposagen Biopharmaceuticals
  378. TriumviraImmunologics
  379. TVAX Biomedical
  380. TVM  Capital
  381. Two Blades Foundation
  382. TxCell
  383. UCLA Jonsson Comprehensive Cancer Center
  384. UNC Lineberger Comprehensive Cancer Center
  385. uniQure
  386. United Therapeutics 
  387. Universal Cells
  388. University College London 
  389. University Health Network, Toronto
  390. University Medical Center Utrecht
  391. University of Birmingham 
  392. University of California, Berkeley
  393. University of Florida
  394. University of Lausanne
  395. University of Milano-Bicocca 
  396. University of Minnesota
  397. University of Oxford
  398. University of Pennsylvania
  399. University of Zurich
  400. Unum Therapeutics 
  401. Uppsala University
  402. Utrecht Holdings
  403. Vaccinogen
  404. Valeant Pharmaceuticals
  405. venBio
  406. Venrock
  407. Versant Ventures
  408. Vertex
  409. VGXI
  410. Vical
  411. Viking Global Investors
  412. ViroMed
  413. VorBiopharma
  414. Weill Cornell Graduate School of Medical Sciences
  415. Wellington Management
  416. West China Hospital
  417. Woodford Investment Management
  418. Wunderlich
  419. WuXiAppTec
  420. Wyeth (Pfizer)
  421. X-Body
  422. Xijing Hospital
  423. Xinqiao Hospital
  424. Xuzhou Medical College
  425. Zhujiang Hospital
  426. ZIOPHARM Oncology
 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security